<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406900</url>
  </required_header>
  <id_info>
    <org_study_id>MIA</org_study_id>
    <nct_id>NCT00406900</nct_id>
  </id_info>
  <brief_title>Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors
      metastasize to the liver. So far no sensitive or specific serological tumor marker is
      routinely used. The marker &quot;Melanoma inhibitory activity&quot; is a promising marker. Study
      hypothesis is to detect metastatic lesions in an early stage. This would increase life
      expectance of our patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA
      the marker MIA is evaluated. An increase of MIA serum level will lead to search for
      metastasis by oncologists.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 1999</start_date>
  <completion_date>September 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>560</enrollment>
  <condition>Melanoma</condition>
  <condition>Radiotherapy</condition>
  <condition>Metastatic Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Treatment of metastatic disease</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  uveal melanoma (With/without overt metastatic disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich C Schaller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrich C Schaller, MD</last_name>
    <phone>+49/89/5160</phone>
    <phone_ext>3811</phone_ext>
    <email>ulrich.schaller@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Ophthalmology, University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich C Schaller, MD</last_name>
      <phone>+49895160</phone>
      <phone_ext>3811</phone_ext>
      <email>ulrich.schaller@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich C Schaller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002 Dec;12(6):593-9.</citation>
    <PMID>12459649</PMID>
  </results_reference>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>December 5, 2006</last_update_submitted>
  <last_update_submitted_qc>December 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2006</last_update_posted>
  <keyword>uveal melanoma</keyword>
  <keyword>metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

